Technology | October 19, 2008

New Ostial Stent Positioning System Featured at TCT 2008

The Ostial Pro Stent Positioning System is designed to facilitate precise stent implantation in coronary and renal aorto-ostial lesions, eliminating the guesswork when deploying a stent at the “true” ostium of the vessel.

The gold-plated feet of the Ostial Pro mark the plane of the aortic wall, allowing precise positioning of the stent relative to the true ostium. The device is compatible with any manufacturer’s 6 Fr, 7 Fr or 8 Fr guiding catheter and any manufacturer’s stent platform.

Ostial Solutions LLC said clinical testing demonstrates stent positioning accuracy to within /- 0.5 mm.

The Ostial Pro helps minimizes the risk of the stent being deployed too proximal to the ostium, the maker said. Should the stent protrude into the aorta, future vessel re-engagement becomes very challenging, often leaving CABG as the patient’s only available revascularization option.

The system is also said to reduces the need for a second stent, because if the stent is deployed distal to the ostium, an additional stent is typically required. The company said a second stent increases costs and can cause metal overlap, thrombosis risk and associated restenosis.

The device can help decreases overall procedure time by reducing fluoro time and contrast use typically required to place an aorto-ostial stent, the company said.

Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init